Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer Announced
“We are very pleased with our recent FDA interactions as we continue to work collaboratively with the Agency to align on the most expeditious path to advance IMNN-001 into Phase 3 and toward potential commercialization for the thousands of women with newly diagnosed advanced ovarian cancer in need of additional treatment options,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “The FDA’s agreement with our plan to meet key CMC requirements is highly encouraging, establishing our ability to produce our gene-mediated therapeutic for our Phase 3 pivotal trial as well as creating a highly cost-efficient framework for potential commercialization.”
Share:
More News
PharmaMar has submitted a Marketing Authorization Application to the European Medicines Agency for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer, whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide. The MAA submission
“At SR One, our mission is to invest in companies that we believe have the ability to innovate and advance transformational new therapies in areas of high unmet medical need,” said Simeon George, M.D., Chief Executive Officer and Managing Partner at SR One. “Fore Bio is focused on resetting the
The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of TACE-progression-free survival (TACE PFS*), and the other primary endpoint of overall survival (OS) is immature at the prespecified first interim analysis. Meanwhile, a clinically meaningful PFS by RECIST v1.1** was also observed. Detailed findings from
“The positive CHMP recommendation for the Itovebi-based regimen represents a significant step towards providing people in the EU with PIK3CA-mutated, ER-positive advanced breast cancer with a targeted therapy in the first-line setting,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This recommendation is
